TWI878289B - 抗ｃｄ３８抗體和調配物 - Google Patents

抗ｃｄ３８抗體和調配物 Download PDF

Info

Publication number
TWI878289B
TWI878289B TW109113639A TW109113639A TWI878289B TW I878289 B TWI878289 B TW I878289B TW 109113639 A TW109113639 A TW 109113639A TW 109113639 A TW109113639 A TW 109113639A TW I878289 B TWI878289 B TW I878289B
Authority
TW
Taiwan
Prior art keywords
antibody
amino acid
seq
acid sequence
cells
Prior art date
Application number
TW109113639A
Other languages
English (en)
Chinese (zh)
Other versions
TW202104269A (zh
Inventor
貝堤翠西 卡梅隆
馬里耶勒 凱隆布隆戴爾
傑奎斯 仲馬
艾倫 富尼耶
喬納森 金斯伯里
辛德琳 萊蒙
布萊恩 莫瑞
奈森 奧斯博格
薩凱 帕特克
奧多 安琪拉 瓦伊倫
張子川
Original Assignee
法商賽諾菲公司
美商健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司, 美商健臻公司 filed Critical 法商賽諾菲公司
Publication of TW202104269A publication Critical patent/TW202104269A/zh
Application granted granted Critical
Publication of TWI878289B publication Critical patent/TWI878289B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW109113639A 2019-04-23 2020-04-23 抗ｃｄ３８抗體和調配物 TWI878289B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
US201962859699P 2019-06-10 2019-06-10
US62/859,699 2019-06-10
EP20305146 2020-02-17
EP20305146.1 2020-02-17
EP20305145 2020-02-17
EP20305145.3 2020-02-17

Publications (2)

Publication Number Publication Date
TW202104269A TW202104269A (zh) 2021-02-01
TWI878289B true TWI878289B (zh) 2025-04-01

Family

ID=70739160

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109113639A TWI878289B (zh) 2019-04-23 2020-04-23 抗ｃｄ３８抗體和調配物

Country Status (15)

Country Link
EP (1) EP3958898A1 (https=)
JP (1) JP7602485B2 (https=)
KR (1) KR20220003562A (https=)
CN (2) CN114269375A (https=)
AU (1) AU2020261039A1 (https=)
BR (1) BR112021021060A2 (https=)
CA (1) CA3137365A1 (https=)
CO (1) CO2021015462A2 (https=)
IL (1) IL287477A (https=)
MA (1) MA55761A (https=)
MX (1) MX2021012967A (https=)
MY (1) MY206426A (https=)
SG (1) SG11202111602YA (https=)
TW (1) TWI878289B (https=)
WO (1) WO2020219681A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2025245526A1 (en) * 2024-05-24 2025-11-27 Research Institute At Nationwide Children's Hospital Cd-38 protein binding compositions and methods related thereto
CN120535629B (zh) * 2025-04-22 2026-01-23 西安市中心血站（陕西省血液中心） 一种用于抑制cd38单抗对输血相容性检测干扰的抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047242A2 (en) * 2006-10-19 2008-04-24 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
TW201806617A (zh) * 2016-06-30 2018-03-01 賽特瑞恩股份有限公司 穩定之液體醫藥調配物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
CN103172731A (zh) * 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
SG10201603411WA (en) * 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
DK3827845T3 (da) * 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
SG11201910134SA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2019064263A1 (en) * 2017-09-29 2019-04-04 Janssen Biotech, Inc. NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS
CN108752475B (zh) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 抗人cd38抗体及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047242A2 (en) * 2006-10-19 2008-04-24 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
TW201806617A (zh) * 2016-06-30 2018-03-01 賽特瑞恩股份有限公司 穩定之液體醫藥調配物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Wang, X., Mathieu, M., & Brezski, R. J. IgG Fc engineering to modulate antibody effector functions. Protein & cell 9(1) 2018 63-73. *

Also Published As

Publication number Publication date
JP7602485B2 (ja) 2024-12-18
CN120757645A (zh) 2025-10-10
BR112021021060A2 (pt) 2021-12-14
IL287477A (en) 2021-12-01
WO2020219681A1 (en) 2020-10-29
MX2021012967A (es) 2022-01-18
KR20220003562A (ko) 2022-01-10
EP3958898A1 (en) 2022-03-02
CO2021015462A2 (es) 2021-12-10
MA55761A (fr) 2022-03-02
JP2022529502A (ja) 2022-06-22
CN114269375A (zh) 2022-04-01
CA3137365A1 (en) 2020-10-29
MY206426A (en) 2024-12-17
SG11202111602YA (en) 2021-11-29
AU2020261039A1 (en) 2021-12-09
TW202104269A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
US12415854B2 (en) Antibodies to TIGIT
US20240400700A1 (en) Ccr8 antibodies for therapeutic applications
AU2021205877B2 (en) Anti-CCR8 antibodies and uses thereof
TWI844073B (zh) 介白素-21突變蛋白及治療方法
TWI878289B (zh) 抗ｃｄ３８抗體和調配物
JP2021525082A (ja) 抗ｓｉｒｐａ抗体およびその使用法
RS66218B1 (sr) Anti-cd154 antitela i njihove upotrebe
CN110546163A (zh) 抗-tigit抗原结合蛋白及其使用方法
JP7678802B2 (ja) Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法
KR20190124247A (ko) Csf1r-기반 키메라 단백질
US20230416395A1 (en) Anti-cd38 antibodies and formulations
JP2021518138A (ja) 抗ｉｌ−２７抗体及びその使用
KR20220031616A (ko) 치료요법에 사용하기 위한 항-소르틸린 항체
RU2826957C2 (ru) Антитела к cd38 и составы
CA3176246C (en) Antibodies to tigit
HK40115111A (zh) 抗pilra抗体、其用途以及相关方法和试剂
KR20230124910A (ko) 염증성 피부 상태 치료 방법
HK40119780A (zh) Cd3/bcma/cd38三特异性抗体
BR122024025431B1 (pt) Uso de um anticorpo anti-ccr8 em combinação simultânea, separada ou sequencial com um ou mais compostos terapeuticamente ativos adicionais para induzir adcp em um paciente humano com um tumor
HK40042330B (zh) 抗-sirpa抗体及其使用方法